Human Thrombomodulin/BDCA-3 Antibody

Catalog #: MAB39471 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB39471
MAB39471-SP

Product Details

Supplemental Products

Reviews

Summary Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human Thrombomodulin/BDCA-3 Antibody Summary

Species Reactivity

Human

Specificity

Detects human Thrombomodulin/BDCA-3 in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant mouse Thrombomodulin is observed.

Source

Monoclonal Mouse IgG_2A Clone # 501727

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Mouse myeloma cell line NS0-derived recombinant human Thrombomodulin/BDCA-3
Ala19-Ser515
Accession # P07204(Val473)

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Applications

Recommended Concentration

Sample

Western Blot

1 µg/mL

Recombinant Human Thrombomodulin/BDCA-3

Immunoprecipitation

25 µg/mL

Conditioned cell culture medium spiked with Recombinant Human Thrombomodulin/BDCA-3 (Catalog # 3947-PA), see our available Western blot detection antibodies

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Thrombomodulin/BDCA-3

Encoded by the THBD gene, Thrombomodulin is also known as blood dendritic cell antigen 3 (BDCA‑3) and designated CD141. The deduced amino acid (aa) sequence of human THBD predicts a signal peptide (aa 1‑18) and a mature chain (aa 19‑575) that consists of following domains: C‑type lectin (aa 31‑169), EGF‑like (aa 241‑281, aa 284‑324, aa 325‑363, aa 365‑405, aa 404‑440, and aa 441‑481), transmembrane (aa 516 to 539) and cytoplasmic (aa 540‑575). The region used as an immunogen consists of aa 19‑515, corresponding to the extracellular portion of the type I membrane protein. Predominantly synthesized by vascular endothelial cells, THBD inhibits coagulation and fibrinolysis (1‑3). It functions as a cell surface receptor and an essential cofactor for active thrombin, which in turn activates protein C and thrombin‑activatable fibrinolysis inhibitor (TAFI), also known as carboxypeptidase B2 (CPB2). Activated protein C (APC), facilitated by protein S, degrades coagulation factors Va and VIIIa, which are required for thrombin activation. Activated CPB2 cleaves basic C‑terminal aa residues of its substrates, including fibrin, preventing the conversion of plasminogen to plasmin. In addition, THBD gene polymorphisims are associated with human disease and THBD plays a role in thrombosis, stroke, arteriosclerosis, and cancer (4). For example, increased serum levels of THBD, due to protease cleavage, have been associated with smoking, cardiac surgery, atherosclerosis, liver cirrhosis, diabetes mellitus, cerebral and myocardial infarction, and multiple sclerosis (5).

References